期刊文献+

盐酸金刚乙胺颗粒人体生物等效性研究 被引量:2

Bioequivalence Study of Rimantadine Hydrochloride Granules in Chinese Healthy Volunteers
原文传递
导出
摘要 目的用高效液相色谱-质谱法(LC-MS)测定受试者口服盐酸金刚乙胺制剂后的血药浓度,估算受试制剂和参比制剂的药动学参数,评价两种制剂的生物等效性和相对生物利用度。方法采用随机二交叉设计试验,20例男性健康志愿受试者,单剂量口服受试制剂盐酸金刚乙胺颗粒和参比制剂盐酸金刚乙胺片。以LC-MS测定血浆中金刚乙胺的浓度。采用BAPP3.0软件处理计算主要药动学参数。结果受试制剂和参比制剂血浆中金刚乙胺的t1/2分别为(26.46±4.48)和(27.41±4.42)h;ρmax分别为(84.5±17.7)和(93.1±17.8)μg·L-1;tmax分别为(4.08±2.86)和(4.70±3.59)h;AUC0-120h分别为(3204±691)和(3450±724)μg·h·L-1;AUC0-∞分别为(3395±767)和(3661±820)μg·h·L-1;人体相对生物利用度为(93.4±10.8)%。结论2种制剂在健康人体内具有生物等效性。 OBJECTIVE To evaluate the relative bioequivalence of two rimantadine hydrochloride preparations in Chinese healthy volunteers by LC-MS. METHODS A single oral dose of two preparations was given to 20 healthy male volunteers according to a randomized crossover design. Plasma drug concentrations were determined by LC-MS. The pharmacokinetic parameters were calculated by BAPP3.0. RESULTS The main pharmacokinetic parameters of rimantadine in test and reference preparations were as follows: t1/2 (26.46±4.48) and (27.41±4.42) h, ρmax (84.5±17.7) and (93.1±17.8) μg·L^-1, tmax (4.08±2.86) and (4.70±3.59) h, AUC0.120 h (3 204±691) and (3 450±724) μg·h·L^-1, AUC0-∞ (3 395±767) and (3 661 ±820) μg·h·L^-1, respectively. The relative bioavailability of test preparation was (93.4±10.8) %. CONCLUSION The two formulations were bioequivalent in human body.
出处 《中国药学杂志》 CAS CSCD 北大核心 2009年第3期209-212,共4页 Chinese Pharmaceutical Journal
基金 国家科技支撑计划课题(2006BAI14B07)
关键词 盐酸金刚乙胺 药动学 生物等效性 高效液相色谱-质谱法 rimantadinehydrochloride pharmacokinetics bioequivalence LC-MS
  • 引文网络
  • 相关文献

参考文献10

  • 1KEYSER L A, KARL M, NAFZIGER A N, et al. Comparison of central nervous system adverse effects of amatadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients [J].Arch Intern Med, 2000, 160(10): 1485-1488.
  • 2MARRA F, MARRA C A, ST1VER H G. A case for rimantadine to be marketed in Canada for prophylaxis of influenza A virus infection [J]. Can Respir J, 2003, 10(7): 381-388.
  • 3JEFFERSON T, DEEKS J J, DEMICHELI V, et al. Amantadine and rimantadine for preventing and treating influenza A in adults[J]. Cochrane Database Syst Rev, 2004, (3): CD00169.
  • 4CHLADEK J, SISPERA L, MARTINKOVA, et al. Bioequivalence of two rimantadine tablet formulations in healthy male volunteers after single dose administration [J]. Int J Clin Pharmacol Ther, 2001, 39 (4): 179-184.
  • 5RAKESTRAW D. Determination of amantadine in human plasma by capillary gas chromatography using electron-capture detection following derivatization with pentafluorobenzoyl chloride [J]. J PharmBiomedAnal, 1993, 11(8): 699-703.
  • 6HESSELINK M B, DEBOER B G, BREIMER D D, et aL Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative mierodialysis study [J]. PharmRes, 1999, 16(5): 637-642.
  • 7CHOMA N, DAVIS P P, EDOM R W, et al. Quantitation of the enantiomers of rimantadine and its hydroxylated metabolites in human plasma by gas chromatography/mass spectrometry [J]. Biomed Chromatogr, 1992, 6(1): 12-15.
  • 8HIGASHI Y, MATSUMURA H, FUJII Y. Determination of fluvoxamine in rat plasma by high-performance liquid chromatography with pre-column derivatization and fluorescent detection using 4-fluoro- 7-nitro-2, 1, 3-benzoxadiazole [J]. Biomed Chromatogr, 2005, 19(9): 655-662.
  • 9HIGASHI Y, NAKAMURA S, MATSUMURA H, et al. Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2 , 1 , 3-benzoxadiazole as a fluorescent derivatization reagent [J]. Biomed Chromatogr, 2006, 20 (5): 423-428.
  • 10CUI S J, FENG F, LIU H, et al. New method for high-performance liquid chromatographic determination of amantadine and its analogues in rat plasma [J]. J Pharm Biomed Anal, 2007, 44 (5): 1100-1105.

同被引文献15

引证文献2

二级引证文献4

;
使用帮助 返回顶部